Leverage nonclinical development of bispecifics by translational science

Baumann, Andreas; Fischmann, Stephanie; Blaich, Guenter; Friedrich, Matthias

doi:10.1016/j.ddtec.2016.08.001

Cited by 4 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both of the scFv arms can bind to their targets in cynomolgus monkeys and in humans. This BsAb was developed to treat prostate cancer 115 . The PSMA is a transmembrane glycoprotein with an extensive extracellular domain, a transmembrane domain, and an intracellular segment.…”

Section: Amg 212 (Bay2010112)mentioning

confidence: 99%

Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials

Hosseini¹,

Khalili

Baradaran

et al. 2021

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Section: Amg 212 (Bay2010112)mentioning

confidence: 99%

Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials

Hosseini¹,

Khalili

Baradaran

et al. 2021

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

“…Multispecific antibodies may be particularly susceptible to immunogenic liabilities [ 238 , 239 ]. This is because divergence from the natural human antibody repertoire generally increases the potential for immunogenicity and multispecific antibodies are likely to include multiple unnatural features.…”

Section: Polyspecificty and In Vivo Propertiesmentioning

confidence: 99%

Toward Drug-Like Multispecific Antibodies by Design

Sawant

Streu

et al. 2020

IJMS

View full text Add to dashboard Cite

The success of antibody therapeutics is strongly influenced by their multifunctional nature that couples antigen recognition mediated by their variable regions with effector functions and half-life extension mediated by a subset of their constant regions. Nevertheless, the monospecific IgG format is not optimal for many therapeutic applications, and this has led to the design of a vast number of unique multispecific antibody formats that enable targeting of multiple antigens or multiple epitopes on the same antigen. Despite the diversity of these formats, a common challenge in generating multispecific antibodies is that they display suboptimal physical and chemical properties relative to conventional IgGs and are more difficult to develop into therapeutics. Here we review advances in the design and engineering of multispecific antibodies with drug-like properties, including favorable stability, solubility, viscosity, specificity and pharmacokinetic properties. We also highlight emerging experimental and computational methods for improving the next generation of multispecific antibodies, as well as their constituent antibody fragments, with natural IgG-like properties. Finally, we identify several outstanding challenges that need to be addressed to increase the success of multispecific antibodies in the clinic.

show abstract

“…Provenge®[5] :prostatic acid phosphatase; (PROSTVAC[6]: prostate specific antigen, PSA; and BAY2010112[7]: a CD3 and PMSA bispecific monoclonal antibody). These studies are already in the clinic and are demonstrating that activation of the immune system is necessary for anti-tumor responses.…”

mentioning

confidence: 99%

Bispecific protein targets prostate cancer

Burgess¹

2017

Oncotarget

View full text Add to dashboard Cite

Leverage nonclinical development of bispecifics by translational science

Cited by 4 publications

References 35 publications

Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials

Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials

Toward Drug-Like Multispecific Antibodies by Design

Bispecific protein targets prostate cancer

Contact Info

Product

Resources

About